skip to primary navigationskip to content

Microbiotica, the latest spin-out from the Wellcome Trust Sanger Institute

last modified Jan 08, 2017 11:47 AM
Microbiotica, the latest spin-out from the Wellcome Trust Sanger Institute, has received funding from Cambridge Innovation Capital (CIC) and IP Group to use the latest discoveries in the characterisation of our bacteria and their role in health and disease to develop bacteriotherapy - a radical way to treat disease based on using the bacteria themselves.
Microbiotica, the latest spin-out from the Wellcome Trust Sanger Institute

The gut microbiome

  • The Wellcome Trust Sanger Institute has spun out a new company, Microbiotica, to develop bacteriotherapies for a potentially wide range of diseases, based on the natural balance of bacteria that make up the healthy gut microbiome. Microbiotica has received initial funding of £4 million ($4.97 million) from Cambridge Innovation Capital, and another £4 million from IP Group.

    Microbiotica will be based at the Wellcome Genome Campus in Hinxton, Cambridge (U.K.), and exploit research by the Sanger Institute's Host-Microbiotica Interactions Laboratory (HMIL) into the role of the human microbiome in health and disease and its potential clinical applications. Combined DNA sequencing and novel culturing approaches by the HMIL's Trevor Lawley, Ph.D., and Professor Gordon Dougan has already resulted in what they claim is the world’s largest culture collection of intestinal bacteria and reference genome library. Dr. Lawley’s team has in addition derived humanized models for the development of live bacterial therapeutics.

    Microbiotica will harness these resources to identify specific disease-related bacteria, patient-stratification strategies, and novel therapeutics. The firm says harnessing the microbiome could provide opportunities for developing diagnostics and therapies for diseases, including enteric infections, autoimmune and metabolic disorders, cancer, and neurological diseases. In addition, Microbiotica has  been granted exclusive rights to potentially therapeutic bacterial mixes, which it aims to progress into preclinical development during the next year.

    The concept that the gut microbes might be involved in diseases such as neurodegenerative disorders or even spinal trauma may at first sight seem improbable. However, earlier this month California Institute of Technology researchers reported on a functional link between intestinal bacteria and Parkinson’s disease. And in October a GEN podcast detailed Ohio State University research describing the impact that the gut microbiome has on spinal cord injury and the use of probiotics to speed recovery.

    “Our work at the Sanger Institute has shown that the human microbiome is important for health and disease, and is itself a therapeutic target,” commented Dr. Lawley, who has been appointed Microbiotica CSO. “I am delighted that the establishment of Microbiotica will allow us to harness the therapeutic potential of the complex microbial community in the body to create novel treatments and help improve human health.”

    Sam Williams, Ph.D., head of biotech at IP Group, added, “by exploring the fundamentals of gut flora distribution and genetics, Microbiotica has an opportunity to take a lead in the understanding how the microbiome can be used to not only develop new therapeutics for a range of diseases, but also how to stratify patients according to their microbial profile, identify links with disease, and exploit its full potential for human healthcare.”


The new Jeffrey Cheah Biomedical Centre - CITIID

See the home of CITIID being built in this fantastic time-lapse video. From basement to water tight in 17 months. The Jeffrey Cheah Bimedical Centre is now complete and home to the Cambridge Immunology Network Coordinator.


‘Fibroblast’ has been developed from a conversation between Harold Offeh and Dr Alice Denton, a scientist based at the Babraham Institute and a member of the Cambridge Immunology Network. Offeh was particularly interested in the character and roles played by particular cells in the immune system, as well as the immune system’s role as a primary source of protection and care. The film takes as a starting point microscopic images of broblast cells, an area of research for Dr Denton.

FCEs provide interdisciplinary training programmes for students, fellows and continuing education physicians through FOCIS assisted opportunities

Read more